IL-21 in cancer immunotherapy At the right place at the right time

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Santegoets, Saskia J A M ^a   Turksma, Annelies W ^a   Powell, Daniel J ^b   Hooijberg, Erik ^a   Gruijl, Tanja D de ^a  

^a University of Amsterdam   (Netherlands)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive cell transfer; Antigen presenting cell; Common gamma chain cytokine receptor family; DC vaccination; IL 21

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 6; INTERLEUKIN 7; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; HELPER CELL; HUMAN; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; METASTATIC MELANOMA; NATURAL KILLER T CELL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84886945131     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24522     Document Type: Article

References (10)

1. Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 2012; 30:3396-401; PMID:22915661; http://dx.doi.org/10.1200/JCO.2011.40.0655
2. StolfiC, Pallone F, Macdonald TT, Monteleone G. Interleukin-21 in cancer immunotherapy: Friend or foe?. Oncoimmunology 2012; 1:351-4; PMID:22737612; http://dx.doi.org/10.4161/onci.19122
3. Santegoets SJ, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, et al. IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. [Epub ahead of print]. J Transl Med 2013; 11:37; PMID:23402380; http://dx.doi.org/10.1186/1479-5876-11-37
4. Gattinoni L, KlebanoffCA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012; 12:671-84; PMID:22996603; http://dx.doi.org/10.1038/nrc3322
5. Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, et al. Modulating the differentiation status of ex vivocultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother 2013; 62: 727-36; PMID:23207483
6. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013; 5:74ra27; PMID:23447018; http://dx.doi. org/10.1126/scitranslmed.3004916
7. Turksma AW, Bontkes HJ, Ruizendaal JJ, van den Heuvel H, Scholten KB, Santegoets SJ, et al. Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells. Hum Immunol 2013; 74:506-13; PMID:23376456; http://dx.doi.org/10.1016/j.humimm.2013.01.014
8. Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012; 491:264-8; PMID:23064231; http://dx.doi.org/10.1038/nature11501
9. Nara H, Rahman M, Araki A, Jin L, Takeda Y, Asao H. IL-21 isoform is a membrane-bound ligand and activates directly interacted cells. Cytokine 2013; 61:656-63; PMID:23312859; http://dx.doi.org/10.1016/j. cyto.2012.12.010
10. Ansén S, Butler MO, Berezovskaya A, Murray AP, Stevenson K, Nadler LM, et al. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res 2008; 14:6125-36; PMID:18829491; http://dx.doi.org/10.1158/1078-0432.CCR-08-1146